[New human vaccines]

Area of Science:

• Vaccinology
• Pediatric infectious diseases
• Immunology

Background:

• Development of novel protein-based vaccines against serogroup B meningococcus (MenB), exemplified by Bexsero, is advancing, with regulatory review focusing on in vitro data and immunogenicity.
• New influenza vaccine technologies are emerging, including a live attenuated nasal spray vaccine (Fluenz) demonstrating improved pediatric efficacy but with age restrictions, and an MF59-adjuvanted inactivated vaccine (Fluad) initially approved for older adults.

Discussion:

• Regulatory approval for new vaccines like Bexsero relies on preclinical data, with clinical effectiveness assessed post-market. This highlights a common challenge in vaccine development, balancing innovation with robust real-world validation.
• The efficacy and safety profiles of novel influenza vaccines (Fluenz, Fluad) present specific considerations for pediatric populations. Fluenz's use is limited in young children, while Fluad's potential for infants requires thorough safety assessment.

Key Insights:

• Bexsero represents a significant step in MenB vaccine development, pending regulatory approval based on established preclinical and immunogenicity criteria.
• Novel influenza vaccines offer potential advantages but necessitate careful evaluation for specific age groups, particularly infants and young children, due to safety and efficacy considerations.

Outlook:

• Further clinical trials are essential to confirm the real-world effectiveness and long-term safety of both meningococcal B and advanced influenza vaccines.
• The development pipeline suggests a trend towards more targeted and potentially more effective vaccines, but pediatric safety and efficacy remain critical areas for ongoing research and regulatory scrutiny.